Yahoo Web Search

Search results

1. • 

     HanxBio announces the publication of a research paper in Scientific Reports on preclinical...

     FOX 59 Indianapolis· 3 days ago

     HanxBio today announced that it has published a research article titled "Narazaciclib, a novel...

2. • 

     FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com

     Investing.com· 4 days ago

     Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to its drug...

3. • 

     Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

     Investor's Business Daily· 21 hours ago

     That could be why the first generation of radiopharmaceuticals were flops, Seth, the Actinium CEO,...

4. • 

     Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study

     Zacks via Yahoo Finance· 7 days ago

     Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its...

5. • Kura Oncology Gets Breakthrough Designation For Leukemia Therapy

     Morningstar· 4 days ago

     By Ben Glickman Kura Oncology said Monday it received a breakthrough therapy designation from regulators for ziftomenib, its potential treatment for a form of leukemia. The San Diego-based biopharmaceutical company said the U.S. Food and

6. • Vor Biopharma’s (VOR) “Outperform” Rating Reiterated at Wedbush

     ETF DAILY NEWS· 5 hours ago

     Wedbush reissued their outperform rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report released on Tuesday, Benzinga reports. Wedbush currently has a $11.00 price ...

7. • Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

     Morningstar· 4 days ago

     Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML ...

8. • Kura Oncology, Inc. (NASDAQ:KURA) Stock Holdings Lessened by Mirae Asset Global Investments Co. Ltd.

     ETF DAILY NEWS· 4 hours ago

     Mirae Asset Global Investments Co. Ltd. lessened its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 5.7% in the fourth quarter, according to the company in its most ...

9. • Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald

     Roanoke-Chowan News-Herald· 22 hours ago

     SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will

10. • Deverra Therapeutics Granted FDA Fast Track Designation for DVX101

      Digital Journal· 2 days ago

      Designation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...